Background Myostatin (MSTN) is a key negative regulator of muscle mass in humans and
animals, having direct and indirect influences on molecular regulators of atrophy and …

EVER SINCE ITS DISCOVERY in 1997 (11), myostatin and its negative effects on skeletal
muscle mass have understandably captivated many biomedical, agricultural, and …

Myostatin, a TGF-β family member, is a negative regulator of muscle growth. Here, we
generated transgenic mice that expressed myostatin mutated at its cleavage site under the …

Myostatin deficiency leads to both an increased rate of protein synthesis and skeletal muscle
hypertrophy. However, the mechanisms involved in mediating these effects are not yet fully …

The presence of sufficient skeletal muscle is of paramount importance for body function.
Cachexia can be defined as a wasting syndrome describing the progressive loss of both …

In 1997, McPherron et al. created the so-called Mighty Mouse: owing to the knock-out of a
new member of the TGF-β superfamily of peptides, this mouse line was extremely …

Myostatin inhibition is one of the promising strategies for treating muscle atrophic disorders,
including muscular dystrophy. It is well-known that the myostatin prodomain derived from the …

Myostatin is a potent negative regulator of skeletal muscle mass, but its role in human
skeletal muscle hypertrophy and atrophy is sparsely described. Muscle biopsies were …

Myostatin, a negative regulator of muscle cell growth, is highly conserved across species.
The loss of functional Myostatin is known to cause the “double-muscled” phenotype in …

Myostatin is a member of the transforming growth factor-beta/bone morphogenetic protein
(TGF-β/BMP) super-family of secreted factors that functions as a potent inhibitor of skeletal …